Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01702558
Title A Combination Study of Kadcyla (Trastuzumab Emtansine) and Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer and Patients With HER2-Positive Locally Advanced / Metastatic Gastric Cancer
Recruitment Terminated
Gender
Phase Phase II
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

Her2-receptor positive breast cancer

stomach cancer

Therapies

Ado-trastuzumab emtansine

Ado-trastuzumab emtansine + Capecitabine

Age Groups: adult
Covered Countries CAN


No variant requirements are available.